Discontinuation report LYNPARZA
| Report ID | 134652 |
| Drug Identification Number | 02454408 |
| Brand name | LYNPARZA |
| Common or Proper name | olaparib |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | OLAPARIB |
| Strength(s) | 50MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | Bottle of 112 capsules |
| ATC code | L01XX |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2021-12-01 |
| Actual discontinuation date | 2021-01-11 |
| Remaining supply date | 2021-01-11 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | There are no known supply of this drug available for sale on the market |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. Veuillez contacter le Service d'information médicale d'AstraZeneca Canada pour toute question spécifique au 1-800-668-6000 (EN) ou au 1-800-461-3787 (FR) ou par courriel : [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2021-02-25 | French | Compare |
| v2 | 2021-02-25 | French | Compare |
| v1 | 2021-02-25 | English | Compare |
Showing 1 to 3 of 3